189 related articles for article (PubMed ID: 34782371)
1. Chk1 Inhibition Potently Blocks STAT3 Tyrosine705 Phosphorylation, DNA-Binding Activity, and Activation of Downstream Targets in Human Multiple Myeloma Cells.
Zhou L; Pei X; Zhang Y; Ning Y; Li L; Hu X; Chalasani SL; Sharma K; Nkwocha J; Yu J; Bandyopadhyay D; Sebti SM; Grant S
Mol Cancer Res; 2022 Mar; 20(3):456-467. PubMed ID: 34782371
[TBL] [Abstract][Full Text] [Related]
2. Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells.
Li L; Hu X; Nkwocha J; Sharma K; Kmieciak M; Mann H; Zhou L; Grant S
Cell Oncol (Dordr); 2023 Oct; 46(5):1369-1380. PubMed ID: 37126127
[TBL] [Abstract][Full Text] [Related]
3. Disruption of Src function potentiates Chk1-inhibitor-induced apoptosis in human multiple myeloma cells in vitro and in vivo.
Dai Y; Chen S; Shah R; Pei XY; Wang L; Almenara JA; Kramer LB; Dent P; Grant S
Blood; 2011 Feb; 117(6):1947-57. PubMed ID: 21148814
[TBL] [Abstract][Full Text] [Related]
4. IL6 Promotes a STAT3-PRL3 Feedforward Loop via SHP2 Repression in Multiple Myeloma.
Chong PSY; Zhou J; Lim JSL; Hee YT; Chooi JY; Chung TH; Tan ZT; Zeng Q; Waller DD; Sebag M; Chng WJ
Cancer Res; 2019 Sep; 79(18):4679-4688. PubMed ID: 31337650
[TBL] [Abstract][Full Text] [Related]
5. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells.
Dai Y; Chen S; Pei XY; Almenara JA; Kramer LB; Venditti CA; Dent P; Grant S
Blood; 2008 Sep; 112(6):2439-49. PubMed ID: 18614762
[TBL] [Abstract][Full Text] [Related]
6. Dissecting the roles of checkpoint kinase 1/CDC2 and mitogen-activated protein kinase kinase 1/2/extracellular signal-regulated kinase 1/2 in relation to 7-hydroxystaurosporine-induced apoptosis in human multiple myeloma cells.
Pei XY; Li W; Dai Y; Dent P; Grant S
Mol Pharmacol; 2006 Dec; 70(6):1965-73. PubMed ID: 16940414
[TBL] [Abstract][Full Text] [Related]
7. Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2.
Pei XY; Dai Y; Youssefian LE; Chen S; Bodie WW; Takabatake Y; Felthousen J; Almenara JA; Kramer LB; Dent P; Grant S
Blood; 2011 Nov; 118(19):5189-200. PubMed ID: 21911831
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of STAT3 signaling and induction of SHP1 mediate antiangiogenic and antitumor activities of ergosterol peroxide in U266 multiple myeloma cells.
Rhee YH; Jeong SJ; Lee HJ; Lee HJ; Koh W; Jung JH; Kim SH; Sung-Hoon K
BMC Cancer; 2012 Jan; 12():28. PubMed ID: 22260501
[TBL] [Abstract][Full Text] [Related]
9. Capsaicin is a novel blocker of constitutive and interleukin-6-inducible STAT3 activation.
Bhutani M; Pathak AK; Nair AS; Kunnumakkara AB; Guha S; Sethi G; Aggarwal BB
Clin Cancer Res; 2007 May; 13(10):3024-32. PubMed ID: 17505005
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of JAK1/STAT3 signaling mediates compound K-induced apoptosis in human multiple myeloma U266 cells.
Park S; Lee HJ; Jeong SJ; Song HS; Kim M; Lee HJ; Lee EO; Kim DH; Ahn KS; Kim SH
Food Chem Toxicol; 2011 Jun; 49(6):1367-72. PubMed ID: 21420464
[TBL] [Abstract][Full Text] [Related]
11. Marek's Disease Virus Disables the ATR-Chk1 Pathway by Activating STAT3.
Lian X; Bao C; Li X; Zhang X; Chen H; Jung YS; Qian Y
J Virol; 2019 May; 93(9):. PubMed ID: 30787154
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 overexpression increases the susceptibility of human U266 myeloma cells to CDK inhibitors through a process involving p130-, p107- and E2F-dependent S phase entry.
Dai Y; Hamm TE; Dent P; Grant S
Cell Cycle; 2006 Feb; 5(4):437-46. PubMed ID: 16479154
[TBL] [Abstract][Full Text] [Related]
13. INCB16562, a JAK1/2 selective inhibitor, is efficacious against multiple myeloma cells and reverses the protective effects of cytokine and stromal cell support.
Li J; Favata M; Kelley JA; Caulder E; Thomas B; Wen X; Sparks RB; Arvanitis A; Rogers JD; Combs AP; Vaddi K; Solomon KA; Scherle PA; Newton R; Fridman JS
Neoplasia; 2010 Jan; 12(1):28-38. PubMed ID: 20072651
[TBL] [Abstract][Full Text] [Related]
14. The novel JAK inhibitor AZD1480 blocks STAT3 and FGFR3 signaling, resulting in suppression of human myeloma cell growth and survival.
Scuto A; Krejci P; Popplewell L; Wu J; Wang Y; Kujawski M; Kowolik C; Xin H; Chen L; Wang Y; Kretzner L; Yu H; Wilcox WR; Yen Y; Forman S; Jove R
Leukemia; 2011 Mar; 25(3):538-50. PubMed ID: 21164517
[TBL] [Abstract][Full Text] [Related]
15. The farnesyltransferase inhibitor L744832 potentiates UCN-01-induced apoptosis in human multiple myeloma cells.
Pei XY; Dai Y; Rahmani M; Li W; Dent P; Grant S
Clin Cancer Res; 2005 Jun; 11(12):4589-600. PubMed ID: 15958645
[TBL] [Abstract][Full Text] [Related]
16. Functional interplay between NF-κB-inducing kinase and c-Abl kinases limits response to Aurora inhibitors in multiple myeloma.
Mazzera L; Abeltino M; Lombardi G; Cantoni AM; Ria R; Ricca M; Saltarella I; Naponelli V; Rizzi FMA; Perris R; Corradi A; Vacca A; Bonati A; Lunghi P
Haematologica; 2019 Dec; 104(12):2465-2481. PubMed ID: 30948493
[TBL] [Abstract][Full Text] [Related]
17. Gambogic acid inhibits STAT3 phosphorylation through activation of protein tyrosine phosphatase SHP-1: potential role in proliferation and apoptosis.
Prasad S; Pandey MK; Yadav VR; Aggarwal BB
Cancer Prev Res (Phila); 2011 Jul; 4(7):1084-94. PubMed ID: 21490133
[TBL] [Abstract][Full Text] [Related]
18. Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
Lee JH; Kim C; Kim SH; Sethi G; Ahn KS
Cancer Lett; 2015 May; 360(2):280-93. PubMed ID: 25697480
[TBL] [Abstract][Full Text] [Related]
19. Co-Inhibition of the DNA Damage Response and CHK1 Enhances Apoptosis of Neuroblastoma Cells.
Ando K; Nakamura Y; Nagase H; Nakagawara A; Koshinaga T; Wada S; Makishima M
Int J Mol Sci; 2019 Jul; 20(15):. PubMed ID: 31362335
[TBL] [Abstract][Full Text] [Related]
20. An activated JAK/STAT3 pathway and CD45 expression are associated with sensitivity to Hsp90 inhibitors in multiple myeloma.
Lin H; Kolosenko I; Björklund AC; Protsyuk D; Österborg A; Grandér D; Tamm KP
Exp Cell Res; 2013 Mar; 319(5):600-11. PubMed ID: 23246572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
